and harms of continued treatment with OP medication. BP and RAL can be discontinued without need for sequential therapy. DEN, PTH/PTHrP, and ROM should be transitioned to anti-resorptive therapy, but the best formulation and duration of treatment is unclear at this time For adults ≥40 years discontinuing GC therapy and continuing to be at high risk of fracture (BMD t-score ≤-2.5, or history of a fragility fracture occurring after ≥12 months of therapy), we conditionally recommend continuing